{"disease":{"id":"dominant-dystrophic-epidermolysis-bullosa","name":"dominant dystrophic epidermolysis bullosa"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04917887","title":"Long-Term Follow-up Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT04917874","title":"A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT04491604","title":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}